Recent advances in the generation of human monoclonal antibody

Makiko Yamashita, Yoshinroi Katakura, Sanetaka Shirahata

Research output: Contribution to journalReview article

17 Citations (Scopus)

Abstract

The use of monoclonal antibodies (mAbs) has now gained a niche as an epochal breakthrough in medicine. Engineered antibodies (Abs) currently account for over 30% of biopharmaceuticals in clinical trials. Several methods to generate human mAbs have evolved, such as (1) immortalization of antigen-specific human B cell hybridoma technology, (2) generation of chimeric and humanized antibody (Ab) from mouse Ab by genetic engineering, (3) acquisition of antigen-specific human B cells by the phage display method, and (4) development of transgenic mice for producing human mAbs. Besides these technologies, we have independently developed a method to generate human mAbs by combining the method of in vitro immunization using peripheral blood mononuclear cells and the phage display method. In this paper, we review the developments in these technologies for generating human mAbs.

Original languageEnglish
Pages (from-to)55-60
Number of pages6
JournalCytotechnology
Volume55
Issue number2-3
DOIs
Publication statusPublished - Dec 2007

All Science Journal Classification (ASJC) codes

  • Biotechnology
  • Bioengineering
  • Biomedical Engineering
  • Clinical Biochemistry
  • Cell Biology

Fingerprint Dive into the research topics of 'Recent advances in the generation of human monoclonal antibody'. Together they form a unique fingerprint.

  • Cite this